RxDoctor Payments DataLook up a doctor →

Nicholas Grimm, PA

Physician Assistant · Marinette, WINPI 1104023381

Payments from drug & device makers

$10,341in general payments, 2019–2025

Across 612 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • UCB, Inc.$900
  • Lilly USA, LLC$896
  • Pfizer$711
  • plus $4K from 19 others

What the payments were for

  • Food & beverage$10,02297%
  • Education$3193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,341 in reported general payments places this provider in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

See all physician assistant providers in Wisconsin

Medicare billing

Part B allowed, 2024
$253,896
Medicare patients
1,116
Services billed
4,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab68$681,882
Skyrizi PenRisankizumab-Rzaa32$667,273
Dupixent PenDupilumab96$361,259
OtezlaApremilast42$212,313
Cosentyx Sensoready (2 Pens)Secukinumab27$204,365
RinvoqUpadacitinib25$157,315
Dupixent SyringeDupilumab30$114,100
Cimzia (2 Pack)Certolizumab Pegol11$92,193
Clobetasol Propionate219$8,133
Doxycycline Monohydrate212$5,740
Triamcinolone Acetonide398$3,986
Acitretin11$2,572
Clindamycin Phosphate71$2,113
Metronidazole27$1,692
Minocycline Hcl45$1,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$419$212,31342 claims
AbbVieRinvoq$1,452$157,31525 claims
UCB, Inc.Cimzia (2 Pack)$900$92,19311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

Other physician assistant in Marinette

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →